Signal
Regeneron's LAG-3 inhibitor fails phase 3 melanoma trial, marking second late-stage setback
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-05-18 08:58 UTCUpdated 2026-05-18 11:55 UTC
rss
clinical_trialsdrug_developmentsafety_signals
Trend in the last 24h
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (3 domains)domains are deduped. counts indicate coverage, not truth.3 top sources shown
Overview
Regeneron's phase 3 trial of its LAG-3 inhibitor fianlimab combined with Libtayo in melanoma failed to meet its primary endpoint, not significantly outperforming Keytruda. This unexpected result represents the company's second major late-stage clinical failure within a year and led to a sharp decline in market value.
Entities
Regeneronfianlimab
Score total
1.27
Momentum 24h
3
Posts
3
Origins
3
Source types
1
Duplicate ratio
0%
Why now
- Results were recently announced, marking a fresh setback for Regeneron.
- Follows a prior late-stage trial failure within the past year, compounding concerns.
- Market reaction was immediate, wiping out billions in company valuation.
Why it matters
- Highlights challenges in developing effective LAG-3 inhibitors for cancer immunotherapy.
- Signals potential delays or setbacks in Regeneron's oncology drug pipeline.
- Impacts investor and market confidence in Regeneron's late-stage drug development.
LLM analysis
Recurring claims
- Regeneron's phase 3 trial of its LAG-3 inhibitor fianlimab combined with Libtayo failed to meet its primary endpoint in melanoma.
How sources frame it
- Fierce Biotech: neutral
- Pharmaphorum: neutral
- BioPharma Dive: neutral
This narrative summarizes Regeneron's recent phase 3 melanoma trial failure of its LAG-3 inhibitor fianlimab, highlighting its impact on the company's oncology pipeline and market valuation.
All evidence
All evidence
Regeneron immunotherapy combo comes up short in melanoma trial
BioPharma Dive · biopharmadive.com · 2026-05-18 11:55 UTC
Another LAG-3 setback as Regeneron drug fails phase 3 trial
pharmaphorum · pharmaphorum.com · 2026-05-18 09:19 UTC
A phase 3 trial of Regeneron’s LAG-3 inhibitor has missed its primary endpoint, leaving the biopharma reeling from the second failure of a key late-stage program in the past year.
Fierce Biotech · fiercebiotech.com · 2026-05-18 08:58 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 3Origin domains: 3Duplicates: -
Showing 3 / 0
Top publishers (this list)
- BioPharma Dive (1)
- pharmaphorum (1)
- Fierce Biotech (1)
Top origin domains (this list)
- biopharmadive.com (1)
- pharmaphorum.com (1)
- fiercebiotech.com (1)